Headquartered in New York, NY Fiscal year ends December NASDAQ: SNDX syndax.com
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing and selling cancer therapies.
- **Revuforj (revumenib):** an oral menin inhibitor and the company's main revenue driver. It is FDA-approved for adult and pediatric patients one year and older with relapsed/refractory NPM1-mutated AML or relapsed/refractory KMT2A-translocated acute leukemia. Syndax is running pivotal Phase 3 frontline trials (EVOLVE-2 with venetoclax/azacitidine; REVEAL-ND with intensive chemotherapy). Other trials cover post-transplant maintenance, MRD and myelofibrosis.
- **Niktimvo (axatilimab-csfr):** a first-in-class CSF-1R-blocking antibody approved in the U.S. for chronic GVHD after at least two prior lines of systemic therapy. It is licensed from UCB and co-developed and co-commercialized with Incyte. Syndax records 50% of Niktimvo's net commercial profit as collaboration revenue. Frontline chronic GVHD trials with ruxolitinib and with corticosteroids are ongoing.
- **Pipeline:** SNDX-4321, a mutant-selective allosteric EGFR inhibitor for NSCLC, and SNDX-62122, a next-generation menin inhibitor for myelofibrosis. Both are expected to enter the clinic in 2027. Updated
Big pharma’s appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a…
Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst. The analyst calls on uniQure (NASDAQ:QURE), Syndax Pharmaceuticals (NASDAQ:SNDX), and Erasca (NASDAQ:ERAS) share…
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing and selling cancer therapies. - **Revuforj (revumenib):** an oral menin inhibitor and the company's main revenue driver.
The Wall Street consensus 12-month price target for SNDX is $37.27.
